ARWR (Arrowhead Pharmaceuticals) Total Assets: $2,268.3 Mil (As of Mar. 2026)


ARWR Arrowhead Pharmaceuticals Inc ARWR
49 GF Score
Price $80.50
GF Value $52.13
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Arrowhead Pharmaceuticals Total Assets?

Arrowhead Pharmaceuticals ARWR +1.86% 49 Total Assets is $2,268.3 Mil as of Mar. 2026. GuruFocus rates ARWR with a GF Score™ of 49/100 and a GF Value™ of $52.13 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Arrowhead Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2026 was $2,268.3 Mil.

During the past 12 months, Arrowhead Pharmaceuticals's average Total Assets Growth Rate was 1.70% per year. During the past 3 years, the average Total Assets Growth Rate was 13.90% per year. During the past 5 years, the average Total Assets Growth Rate was 15.60% per year. During the past 10 years, the average Total Assets Growth Rate was 37.60% per year.

During the past 13 years, Arrowhead Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 420.80%. The lowest was -18.50%. And the median was 23.20%.

Total Assets is connected with ROA %. Arrowhead Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2026 was -27.42%. Total Assets is also linked to Revenue through Asset Turnover. Arrowhead Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2026 was 0.04.

Arrowhead Pharmaceuticals  (NAS:ARWR) Total Assets Explanation

Total Assets is connected with ROA %.

Arrowhead Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-530.928/( (1604.181+2268.265)/ 2 )
=-530.928/1936.223
=-27.42 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Arrowhead Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=73.737/( (1604.181+2268.265)/ 2 )
=73.737/1936.223
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Arrowhead Pharmaceuticals Total Assets Related Terms

Arrowhead Pharmaceuticals Total Assets Historical Data

* Premium members only.

The historical data trend for Arrowhead Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arrowhead Pharmaceuticals Total Assets Chart

Arrowhead Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 710.15 691.94 765.55 1,139.80 1,385.30

Arrowhead Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,573.50 1,380.61 1,385.30 1,604.18 2,268.27
ARWR
49GF Score
Arrowhead Pharmaceuticals Inc ARWR
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arrowhead Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Arrowhead Pharmaceuticals's Total Assets for the fiscal year that ended in Sep. 2025 is calculated as

Total Assets=Total Equity (A: Sep. 2025 )+Total Liabilities (A: Sep. 2025 )
=503.416+881.879
=1,385.3

Arrowhead Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=598.916+1669.349
=2,268.3

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $2,268.3 Mil mean?
Arrowhead Pharmaceuticals (ARWR) has a Total Assets of $2,268.3 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Arrowhead Pharmaceuticals and its competitors.
Is Arrowhead Pharmaceuticals' Total Assets too high?
Arrowhead Pharmaceuticals' current Total Assets is $2,268.3 Mil. Overall, Arrowhead Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arrowhead Pharmaceuticals' Total Assets compare to CYTK and TECH?
Arrowhead Pharmaceuticals' Total Assets of $2,268.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Arrowhead Pharmaceuticals and its competitors. Arrowhead Pharmaceuticals's current Total Assets is $2,268.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arrowhead Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Arrowhead Pharmaceuticals (ARWR) is currently considered Significantly Overvalued. The stock's GF Value™ is $52.13, compared to a current price of $80.50 — trading 54.4% above its estimated fair value. The current Total Assets is $2,268.3 Mil. Arrowhead Pharmaceuticals' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Arrowhead Pharmaceuticals (ARWR), the current Total Assets is $2,268.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arrowhead Pharmaceuticals (ARWR) Overvalued in 2026?

Based on GuruFocus' analysis, Arrowhead Pharmaceuticals stock appears to be overvalued. The current stock price of $80.50 is trading 54.4% above its estimated GF Value™ of $52.13. GuruFocus considers Arrowhead Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for ARWR:

  • Total Assets: $2,268.3 Mil
  • GF Value™: $52.13 vs. price of $80.50 (54.4% above fair value)
  • GF Score™: 49/100 with 6 warning signs

No single metric tells the full story. See the ARWR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arrowhead Pharmaceuticals Business Description

Address 177 E Colorado Boulevard, Suite 700, Pasadena, CA, USA, 91105
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
49GF Score

Get the complete analysis for ARWR

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$80.50
Price
$52.13
GF Value